Anti-Human CD194 (CCR4) (Mogamulizumab)
Anti-Human CD194 (CCR4) (Mogamulizumab) (LT1000-GRP)
Products
Description
Clone KW-0761 (Mogamulizumab) is a research-grade, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.1 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1–infected cells and the levels of inflammatory markers related to HTLV-1–Associated Myelopathy.3
Specifications
| Manufacturer Cat# | LT1000 |
|---|---|
| Concentration | ≥ 5.0 mg/ml |
| Formulation | This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. |
| Isotype | IgG1 κ |
| Clone | KW-0761 |
| Target | CD194 |
| Applications | ELISA, FA, FC, IP, WB |
| Antigen | CCR4 is primarily expressed by Th2 and regulatory T cells in addition to expression on leukemic cells in cutaneous T-cell lymphoma (CTCL). |
| Storage | Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| Protein | CD194 |